drugset / Trial / NCT05606380
A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This trial is an open, dose escalation phase I clinical study. Subjects can only enter this study after they meet the inclusion and exclusion criteria.Into subjects will accept HLX60 intravenous infusion, every 3 weeks, treatment until lose clinical benefit, toxicity, death, revocation of informed consent.
Timeline
- Start
- 2022-12-02
- Primary completion
- 2024-08
- Completion
- 2025-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX60 | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Subject | HLX60 | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | HLX60 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | HLX60 | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | HLX60 | Monoclonal antibody | 25 mg/kg | Intravenous |